Senator Ed Markey has requested that TikTok's U.S. joint venture and Oracle provide information regarding the security of American user data and efforts to prevent foreign manipulation of TikTok's content recommendation algorithm. This comes after TikTok's Chinese owner, ByteDance, finalized a deal to establish a majority American-owned joint venture to secure U.S. data and avoid a ban on the app. Oracle is one of the three managing investors in TikTok USDS JV, which will retrain, test, and update TikTok's algorithm using U.S. user data, secured in Oracle's U.S. cloud.

Reliance Steel & Aluminum Co. (RS) has reached an all-time high stock price of 381.3 USD, reflecting a significant upward trend with gains of 29.44% over the past year. This growth is supported by strong Q1 2026 earnings, which surpassed analyst expectations for both EPS and revenue. Despite this, InvestingPro analysis suggests the stock may be overvalued relative to its Fair Value.

MarketAxess Holdings Inc. (MKTX) stock has fallen to a 52-week low of $130.07, representing a 39.66% decline over the past year. Despite this downturn and an oversold RSI, InvestingPro analysis suggests the stock is undervalued, trading at a P/E of 15.59 and PEG of 0.32. This financial technology company recently reported strong Q1 2026 results, exceeding revenue and EPS forecasts.

Activist investor Voss Capital, holding less than 1% of Sempra shares, is urging Sempra to spin off its Texas electric unit, Oncor Electric Delivery Company. Voss believes that an independent Oncor would be beneficial.

Truist Financial downgraded Caesars Entertainment (NASDAQ:CZR) from "buy" to "hold" and lowered its price target to $31, citing limited upside from the current share price. Wall Street's sentiment on CZR is mixed, with an average "Hold" rating and a consensus price target of $32.73, following recent quarterly earnings that missed profit expectations and elevated leverage. The company's stock traded down by $0.10 on Friday, and institutional investors have recently adjusted their holdings.

Mark Kowalzan, Chairman and CEO of Packaging Corp of America (NYSE: PKG), sold 9,266 shares of company stock for a total transaction value of $2,011,426, according to an SEC filing on May 28. While the company exhibits positive revenue growth and prudent debt management, its stock is currently perceived as overvalued based on various metrics like P/E, P/S, and EV/EBITDA ratios. Insider transactions are crucial for investors as they offer insights into a company's financial health and future prospects.

Ronda E Stryker, a director at Stryker (NYSE: SYK), sold 310,000 shares of the company's stock for a total of $96.79 million on May 28, 2026. This insider transaction was disclosed in an SEC Form 4 filing. The article also provides a detailed look at Stryker's financial performance, including revenue growth, profitability metrics, debt management, and market valuation.

Lance Soliday, SVP & Chief Accounting Officer at Expedia Group (NASDAQ: EXPE), sold 940 shares worth $208,547 on May 28. This insider sale comes as Expedia Group's shares were down by 1.09%, trading at $228.34, with the company demonstrating strong revenue growth but facing challenges in debt management and a declining EPS. The article provides a financial overview of Expedia Group, including its profitability metrics and valuation analysis, and explains the significance of insider transactions for investors.

Paycom Software Inc. (PAYC) shares have remained steady on the NYSE as investors assess the company's first-quarter 2026 results and forward valuation multiples. The company reported double-digit year-on-year revenue growth and healthy operating margins, reflecting continued demand for its cloud-based human capital management services. Investors are balancing solid profitability and recurring revenue with questions about growth normalization in the broader software sector and macroeconomic considerations.

Bristol Myers Squibb announced positive results from a late-stage trial for its multiple myeloma drug candidate, mezigdomide. When used as part of a combination regimen, mezigdomide improved cancer-free survival by over 50%. This represents a significant win for the company in the blood cancer treatment sector.